Background: Ligelizumab is an anti‐IgE monoclonal antibody binding IgE with higher affinity than omalizumab that is under clinical investigation for several IgE‐mediated diseases. We previously showed that omalizumab removes IgE bound to FcεRI on plasmacytoid dendritic cells (pDCs) and restores their ability to produce IFN‐α and regulatory T cells (Tregs). The aim of this work is to investigate the capacity of ligelizumab to regulate functional properties of pDCs in comparison with omalizumab.Methods: pDCs were isolated from atopic donors and IgE was detached from FcεRI on pDCs with designed ankyrin repeat protein (DARPin) bi53‐79. pDCs were resensitized with IgE alone or in the presence of ligelizumab or omalizumab prior to IgE‐FcεRI crosslinking and Toll‐like receptor 9 (TLR9) stimulation. Flow cytometry, ELISA, coculture experiments and intranuclear staining were performed to determine cytokine production and Treg generation. An antigen‐specific model of resensitization and IgE‐crosslinking was also performed.Results: The levels of serum total free IgE show a non‐linear positive correlation with the frequency of IgE+ pDCs displaying IgE bound to FcεRI within the 43 individual donors included in the study. Ligelizumab displays stronger capacity than omalizumab to block the binding of free IgE to FcεRI on human pDCs, resulting in a greater restoration of TLR9‐L‐induced IFN‐α production. Ligelizumab also restores the ability of pDCs to generate FOXP3+ Tregs as previously reported for omalizumab.Conclusions: The uncovered novel molecular mechanisms of ligelizumab to regulate functional properties of pDCs from atopic donors might have important clinical implications for anti‐IgE treatments in different IgE‐mediated diseases.
Background: A causal relationship between Crohn's disease (CD) and asthma is reported, but the underlying mechanisms are not fully understood. We sought to investigate the role of IgE and IgE‐mediated pathways in the pathophysiology of CD. Methods: 20 CD patients, 10 allergic patients without inflammatory bowel disease, and 10 healthy donors (HD) were included in the study. Total serum IgE was quantified by ELISA. Circulating IgE + and FcεRIα + immune cells, as well as specific CD4 + T cell populations, were determined by flow cytometry. Gene set enrichment signatures from available single‐cell (sc)RNAseq datasets of the intestine from CD patients were analyzed. Purified plasmacytoid dendritic cells (pDCs) from CD patients were cocultured with naïve CD4 + T cells to assess Tregs generation. Results: CD patients, similar to allergic non‐CD patients, displayed significantly higher numbers of circulating IgE + or FcεRIα + immune cells than HD. The percentage of blood IgE + or FcεRIα + pDCs was significantly higher in CD than HD and similar to allergic non‐CD patients. CD patients showed significantly higher numbers of effector memory CD4 + T cells and lower numbers of FOXP3 + Tregs than HD. scRNAseq data from CD patients confirmed that Tregs imbalance and overactivation of IgE‐mediated pathways take place also in gut tissues of children and adults, suggesting IgE could interfere in the pDC‐Tregs axis. In vitro functional experiments demonstrated that IgE‐crosslinking on pDCs from CD patients impairs Treg generation, which was restored by the anti‐IgE mAb omalizumab. Conclusions: IgE might play an unprecedented role in CD by impairing the capacity of pDCs to generate Tregs, which could represent a novel mechanism contributing to CD to be exploited for alternative therapeutic interventions.